Moreover, when we evaluated CXCL10 expression after prolonged combination treatment with regorafenib and anti-PD1 antibodies (for 1 week in the PK studies), we found increased protein expression level of CXCL10 for the intermediate (10 mg/kg) and the high dose (20 mg/kg) of regorafenib but not for the low dose (5 mg/kg) by western blot analysis in whole tumor tissue lysate (figure 3J, K). This evidence concerns the gene PDCD1 and neoplasm.